$AAPG

Ascentage Pharma (AAPG) announced that its drug lisaftoclax (APG-2575) received Breakthrough Therapy Designation in China for treating treatment-naïve CLL/SLL. The designation accelerates development and review for the combination therapy. Lisaftoclax is already approved in China for previously treated CLL/SLL patients and is in global Phase III trials.

Citigroup initiated coverage on Ascentage Pharma Group International (AAPG) with a Buy rating and $46 price target. GuruFocus values AAPG at $23.79, suggesting 36.7% undervaluation. The company has a GF Score of 54/100, indicating moderate performance with strong growth but weak profitability. AAPG focuses on biotech therapies for cancer and other diseases.

Citizens initiated coverage on Ascentage Pharma (NASDAQ:AAPG) with a Market Outperform rating and a $35.00 price target. The biotech company, focused on oncology, has a $1.375B market cap and trades near its 52-week low. Analysts cite potential value from Phase 3 data expected in 2027 and strong revenue growth, though the company is not yet profitable. Revenue surged 65% in the last year, with a 29.3% increase in the first half of 2026 to $44.5M.

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss h

Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. Miyara will lead global business development, while Ziegler will oversee commercialization outside China and in the US. Both report to CEO Dajun Yang, according to the company.

The article is promotional and does not provide verifiable Phase 1b clinical results for Ascentage Pharma’s olverembatinib. It instead discusses AI and robotics themes and promotes subscription offers from Insider Monkey, including claims of past returns and “upside potential” for an unidentified “$3 stock,” without citing specific Phase 1b data.

Ascentage Pharma (NASDAQ: AAPG) announced new clinical data from six trials presented at ASCO 2026, featuring three lead drug candidates: olverembatinib, lisaftoclax, and alrizomadlin. Highlights include a 30% objective response rate (ORR) and an 80% disease control rate (DCR) in heavily pretreated pediatric solid tumors using a combination of alrizomadlin and lisaftoclax, with a manageable safety profile. The company also reported promising results for olverembatinib in chronic myeloid leukemia (CML) and SDH-deficient tumors, with two global Phase 3 registrational trials currently enrolling patients.

Ascentage Pharma director Lu Simon Dazhong has filed an amended initial ownership report (Form 3/A) to correct inaccuracies in his previously reported equity holdings. The amendment clarifies his direct ownership of 41,457 Ordinary Shares, options over 17,965 Ordinary Shares, and 27,965 restricted share units, along with detailed vesting schedules for the options and RSUs. This filing does not represent new transactions but rather a correction of previously misstated or omitted information.

Ascentage Pharma director Marina Bozilenko has filed an amended Form 3 to correct previously misreported details regarding her stock options and Restricted Share Units (RSUs). The amendment clarifies that her stock options cover 17,965 Ordinary Shares with an exercise price of 8.1400 per share, vesting monthly over a year starting November 26, 2025. Her RSUs, covering 27,965 Ordinary Shares, vest in four equal annual increments from November 26, 2026, to November 26, 2029, with no exercise price.

Ascentage Pharma will present data from four preclinical studies of its innovative drug candidates at the American Association of Cancer Research (AACR) Annual Meeting 2026. These presentations will highlight the latest preclinical results for Olverembatinib (HQP1351), APG-2449, and APG-5918, showcasing their efficacy and synergistic effects in various cancer models. The AACR Annual Meeting is a critical event for sharing breakthroughs and advancements in cancer science and medicine.